Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2008
10/30/2008WO2008055940A3 Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
10/30/2008WO2007121432A3 Benzoazepin-oxy-acetic acid derivatives as ppar-delta agonists used for the increase of hdl-c, lower ldl-c and lower cholesterol
10/30/2008US20080269585 System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor
10/30/2008US20080269349 administering an isolated astaxanthin and a mono- or di-ester thereof; controlling cytokine or TGF- alpha -related gene expression; reducing muscle atrophy, treating diabetes
10/30/2008US20080269344 respiratory diseases such as asthma, chronic obstructive pulmonary disease, bronchitis; useful in the treatment of nervous system injury and premature labor; 1-{2-[N-2-(4-hydroxy-3-formylaminophenyl)-2-(RS) hydroxyethyl]aminoethyl}-4-[N-(2-phenyl-2-(RS)-hydroxyethyl)amino]phenyl; milveterol
10/30/2008US20080269341 administering to patient fenretinide for treating an infectious disease, or bone disease osteopenia or osteoporosis; decreasing arachidonic acid levels, increasing docosahexaenoic acid; for increase osteoblast formation; diagnostic and screening disease based on the lipid level
10/30/2008US20080269336 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
10/30/2008US20080269330 Nutrition Containing Fat Blend
10/30/2008US20080269311 vildagliptin, MK-0431, saxagliptin etc as dipeptidyl-peptidase inhibitor; tegaserod, cisapride, nor-cisapride, renzapride, zacopride, mosapride, prucalopride, buspirone, and norcisapride interect with a 5-HT4 receptor, and cilansetron, ramosetron, azasetron, dolasetron, ramosetron interect with 5-HT3 R
10/30/2008US20080269307 Quantity of acetyl L-carnitine to be administered is 0.1 to 2 g/day, while the dose of biotin is 1 to 8 mg/day
10/30/2008US20080269303 Diaryloxazole carboxamide derivatives for treating a disease selected from appetite disorder, metabolic disorder, gastrointestinal disorder, inflammatory phenomena, immune system disease, psychotic disorder, alcohol dependency and nicotine dependency
10/30/2008US20080269296 Diaryl ethers as opioid receptor antagonists
10/30/2008US20080269287 Substituted Pyridone Derivative
10/30/2008US20080269283 Arylsulfones and uses related thereto
10/30/2008US20080269282 Including semicarbazide-sensitive amine oxidase (vascular adhesion protein-1, VAP-I), and therapeutic use in inflammatory diseases, diabetes and its associated complications, atherosclerosis, neurodegenerative diseases, obesity, hypertension and cancer; N1-hydroxy-N2-[(4-bromophenyl)carbonyl]glycinamide
10/30/2008US20080269281 Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs
10/30/2008US20080269279 Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators
10/30/2008US20080269277 Pyrrolopyridine-2-Carboxylic Acid Hydrazides
10/30/2008US20080269271 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders
10/30/2008US20080269267 Anticancer agents; rheumatic diseases; asthma; chronic obstructive pulmonary disease; neurodegenerative diseases; metabolic disorders
10/30/2008US20080269260 Using a purine compound; antiallergens; antiinflammatory agents; cognition activators; drug abuse; schizophenia; Alzheimer's disease; Parkinson's disease
10/30/2008US20080269257 Use of Substituted 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A] Pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-A] Pyrimidin-5(1H)one Derivatives
10/30/2008US20080269255 Hypotensive agents; atherosclerosis; congestive heart failure; hypertrophy; cardiomyopathy; diabetic nephropathy; restenosis; cognition activator; Alzheimer's disease; anxiolytic agents
10/30/2008US20080269254 Antiproliferative agents; anticancer agents; graft versus host disease; rheumatic diseases; vision defects; cardiovascular disorders
10/30/2008US20080269233 Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
10/30/2008US20080269220 Antidiabetic agents; obesity; insulin resistance; neurodegenerative diseases; Alzheimer's disease
10/30/2008US20080269204 Benzolactam boronic acid compounds; blocking inflammatory cytokines and tumor necrosis ; phosphodiesterase inhibitor; antiarthritic agents; psoriasis; inflammatory bowel disorders
10/30/2008US20080269201 Central nervous system disorders; respiratory system disorders; sexual or reproductive disorders; gastrointestinal disorders; eating disorders; antidiabetic agents; anticancer agents
10/30/2008US20080269199 Therapy for obesity, diabetes, sleep disorders, Alzheimer's disease, Parkinson's disease; attention deficit disorders; antiepileptic agents; schizophrenia; antidepressants; anxiolytic agents
10/30/2008US20080269197 antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia
10/30/2008US20080269189 Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer
10/30/2008US20080269184 Niosome Having Metal Porphyrin Complex Embedded Therein, Process For Producing The Same And Drug With The Use Thereof
10/30/2008US20080269170 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors
10/30/2008US20080269167 Preparation Comprising Iron(III) Complex Compounds And Redox-Active Substance(s)
10/30/2008US20080269166 O-desmethylvenlafaxine succinate; tablet, capsule; sustained release; hydroxypropylmethyl cellulose rate controlling polymer; microcrystalline cellulose binder; depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease
10/30/2008US20080269155 Remedy or preventive for kidney disease and method of diagnosing kidney disease
10/30/2008US20080269149 Adeno-associated virus (AAV); genetic engineering; parvoviruses; gene therapy; muscle delivery; glioblastoma; Parkinson's Disease
10/30/2008US20080269136 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
10/30/2008US20080269134 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
10/30/2008US20080269130 Methods and compositions for treating hypoglycemic disorders
10/30/2008US20080269128 Albumin Fusion Proteins
10/30/2008US20080269127 Albumin Fusion Proteins
10/30/2008US20080269126 Albumin Fusion Proteins
10/30/2008US20080269125 Albumin Fusion Proteins
10/30/2008US20080269118 Identifying molecule suitable for treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, by determining whether candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which Gpr100 polypeptide comprises specific amino acid sequence
10/30/2008US20080269117 Regulating plasma glucose concentration and/or increasing insulin sensitivity in mammal by administering nutritional or pharmaceutical composition containing protein fraction comprising 10.8 wt % aspartate equivalents, where part is provided by aspartate source containing 12.0 wt % aspartate equivalents
10/30/2008US20080269116 Methods of Inhibiting Proinflammatory Cytokine Expression Using Ghrelin
10/30/2008US20080269114 Y4 Selective Receptor Agonists For Thereapeutic Interventions
10/30/2008US20080269111 Administering to a subject an apolipoprotein-sphingomyelin complex comprising an apolipoprotein and the lipid sphingomyelin in an amount effective to achieve a serum level of free or complexed apolipoprotein in the range of 30 mg/dL to 300 mg/dL after administration; treatment of cardiovascular disease
10/30/2008US20080269110 Non-basic melanin concentrating hormone receptor-1 antagonists
10/30/2008US20080268749 Crotch-Possessing Corrective Garment
10/30/2008US20080268489 Therapeutic polypeptide for use in treatment of heart, hypothermic and cardiovascular disorders
10/30/2008US20080268069 Mixture having effect of improving insulin resistance, effect of suppressing body weight gain, and effect of preventing and improving fatty liver
10/30/2008US20080268066 Synergistic Formulation for Preventing and/or Treating Diabetes
10/30/2008US20080268039 Loquat compositions
10/30/2008US20080268038 Composition of essential amino acids L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-valine and L-threonine
10/30/2008US20080268032 Stabilizing Alkylglycoside Compositions and Methods Thereof
10/30/2008US20080268030 Gene therapy for diabetic ischemic disease
10/30/2008US20080267962 Albumin Fusion Proteins
10/30/2008US20080267941 Nutrition Comprising Betaine Against Muscle Wasting
10/30/2008US20080267933 Using lactobacillus and/or bifidobacterium cultures to control weight gain, prevent obesity, increase satiety, prolong satiation, reduce food intake, reduce fat deposition, improve energy metabolism, enhance insulin sensitivity and treat insulin insensitivity
10/30/2008US20080267932 Lactobacillus Rhamnosus with Body-Fat Reducing Activity and the Foods Containing Them
10/30/2008US20080267926 Exposing embryonic stem cells culture to cells expressing activin receptor-like kinase (ALK) receptor, transplanting tissues into mammal, recovering insulin secreting cells; endocrine cell therapy
10/30/2008US20080267912 Novel inhibitors of glutaminyl cyclase
10/30/2008CA2684707A1 Mo-1, a gene associated with morbid obesity
10/30/2008CA2684634A1 Pyrimidinone derivatives and methods of use thereof
10/30/2008CA2684633A1 Pyrimidinone derivatives and methods of use thereof
10/30/2008CA2684618A1 Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof
10/30/2008CA2684453A1 Medicaments and methods to treat autoimmune disease and cancer
10/30/2008CA2683948A1 Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
10/30/2008CA2683534A1 Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same
10/30/2008CA2659603A1 Oil producing microbes and methods of modification thereof
10/29/2008EP1986011A2 Peptide epitopes recognized by disease promoting CD4+ T lymphocytes
10/29/2008EP1985635A1 Process for producing polysaccharide from coffee bean or/and coffee extraction residue
10/29/2008EP1985632A2 Use of VEGF2 antibodies for inhibiting photoreceptor cell proliferation
10/29/2008EP1985308A2 Water-soluble compositions of bioactive lipophilic compounds
10/29/2008EP1985296A1 New substituted pentabasic azaheterocyclic compounds and its use of treating protein aging disease
10/29/2008EP1985295A1 Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
10/29/2008EP1984370A1 Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
10/29/2008EP1984360A2 Compounds and methods for modulating fx-receptors
10/29/2008EP1984340A1 Anthranilamide/2-amino-heteroarene carboxamide derivatives
10/29/2008EP1984326A1 Acyclic sulfamide derivatives
10/29/2008EP1984324A1 Mandelic hydrazides
10/29/2008EP1983976A2 Composition comprising a polyunsaturated fatty acid for improving membrane composition
10/29/2008EP1983849A1 A food composition comprising amino acids
10/29/2008EP1828134B1 Piperazinyl pyridine derivatives as anti-obesity agents
10/29/2008EP1556055B1 Cyclic nucleotide phosphodiesterase inhibitors having a benzodiazepine structure and their use in therapy
10/29/2008EP1474164B1 Use of amylin, amylin analogs and amylin derivatives to treat dyslipidemia and triglyceridemia
10/29/2008EP1425264B1 C2-disubstituted indane-1-ol systems and their use as medicaments
10/29/2008EP1406650B1 Use of poly-glu, tyr for neuroprotection therapy of the cns or pns
10/29/2008EP1263739B9 Crystalline salts of 7-¬4-(4-fluorophenyl)-6-isopropyl-2-¬methyl(methylsulfonyl)amino pyrimidin-5-yl -(3r,5s)-3,5-dihydroxyhept-6-enoic acid
10/29/2008EP1222208B1 Polypeptide derivatives of parathyroid hormone (pth)
10/29/2008CN101296916A Dihydroxyanthraquinones and their use
10/29/2008CN101296906A (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
10/29/2008CN101296904A Amide derivatives as kinase inhibitors
10/29/2008CN101296903A Novel indole-containing beta agonists, method for producing them and their use as drugs
10/29/2008CN101296693A Endurance improver
10/29/2008CN101294187A Method for sustained-releasing polypeptide with biological activity and application thereof
10/29/2008CN101293888A Xanthine derivative, production and use thereof as a medicament
10/29/2008CN101293831A Uses of 3-hydroxy fatty acid and its derivative in preparing calcium ion duct modifying agent
1 ... 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 ... 1298